Calidi Biotherapeutics Announces Pricing of $2 Million Registered Direct Offering and Concurrent Private Placement
Calidi Biotherapeutics, Inc. (CLDI)
Company Research
Source: GlobeNewswire
SAN DIEGO, Oct. 23, 2024 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics, Inc. (NYSE AMERICAN: CLDI) (“Calidi” or the “Company”), a clinical-stage biotechnology company developing a new generation of targeted immunotherapies, today announced that it has entered into a definitive securities purchase agreement with certain institutional investors for the purchase and sale of 2,050,000 shares of the Company’s common stock at a price of $1.00 per share of common stock in a registered direct offering. In addition, in a concurrent private placement, the Company will issue to the investors series E warrants to purchase up to 2,050,000 shares of common stock and series F warrants to purchase up to 2,050,000 shares of common stock. The series E warrants have an exercise price of $1.13 per share, will be exercisable six months following the date of issuance and will have a term of one year from the date of exercisability. The series F warrants have an exercise price of $1.13 per share, will be ex
Show less
Read more
Impact Snapshot
Event Time:
CLDI
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CLDI alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CLDI alerts
High impacting Calidi Biotherapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
CLDI
News
- Calidi Biotherapeutics Presents Data Supporting RTNova Systemic Technology to Target Metastatic Lung Cancer [Yahoo! Finance]Yahoo! Finance
- Calidi Biotherapeutics Presents Data Supporting RTNova Systemic Technology to Target Metastatic Lung CancerGlobeNewswire
- Calidi Biotherapeutics Announces Closing of $7.5 Million Public Offering of Common StockGlobeNewswire
- Calidi Biotherapeutics Announces Pricing of $7.5 Million Public Offering of Common StockGlobeNewswire
- Calidi Biotherapeutics Announces Proposed Public OfferingGlobeNewswire
CLDI
Sec Filings
- 11/18/24 - Form 8-K
- 11/15/24 - Form 8-K
- 11/15/24 - Form 424B5
- CLDI's page on the SEC website